MiNK Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $5.8M | $6.3M | $15.5M | $23.1M | $14.0M |
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Interest expense | $110,000 | $93,000 | $28,000 | — | $2.4M |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M |
| Balance Sheet | |||||
| Cash and equivalents | $13.4M | $4.6M | $3.4M | $19.6M | $38.9M |
| Current assets | $13.8M | $5.0M | $3.6M | $20.4M | $39.6M |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
| Current liabilities | $13.0M | $7.0M | $11.4M | $12.7M | $16.5M |
| Stockholders' equity | -$14.2M | -$19.6M | -$18.1M | -$401,303 | $23.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Depreciation and amortization | $181,745 | $215,437 | $204,617 | $121,749 | $77,960 |
| Stock-based compensation | $2.7M | $1.8M | $3.9M | $3.0M | $1.7M |
| Capital expenditure | — | — | $73,561 | $250,046 | $248,983 |
| Free cash flow | — | — | -$15.8M | -$19.1M | -$13.1M |
| Share repurchases | — | — | $0 | — | — |
Shares outstanding 5.0M · Free float 22.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.